Immunome Inc [IMNM] stock prices are up 2.27% to $10.82 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The IMNM shares have gain 27.14% over the last week, with a monthly amount glided 22.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on April 02, 2025, when Lake Street initiated its Buy rating and assigned the stock a price target of $23. Previously, Stephens started tracking the stock with Overweight rating on November 08, 2024, and set its price target to $30. On May 31, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $24 on April 30, 2024. Guggenheim initiated its recommendation with a Buy and recommended $35 as its price target on April 15, 2024. Leerink Partners started tracking with a Outperform rating for this stock on January 29, 2024, and assigned it a price target of $30. In a note dated December 19, 2023, Wedbush initiated an Outperform rating and provided a target price of $12 on this stock.
The stock price of Immunome Inc [IMNM] has been fluctuating between $5.15 and $16.81 over the past year. Currently, Wall Street analysts expect the stock to reach $30.33 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $10.82 at the most recent close of the market. An investor can expect a potential return of 180.31% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
The Immunome Inc [NASDAQ:IMNM] reported sales of 10.94M for trailing twelve months, representing a surge of 184.35%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -19.94%, Pretax Profit Margin comes in at -18.75%, and Net Profit Margin reading is -18.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.86 and Total Capital is -0.7. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Immunome Inc [NASDAQ:IMNM]’s Current Ratio is 10.49. On the other hand, the Quick Ratio is 10.49, and the Cash Ratio is 8.36. Considering the valuation of this stock, the price to sales ratio is 86.06, the price to book ratio is 3.06.
Transactions by insiders
Recent insider trading involved BIENAIME JEAN JACQUES, Director, that happened on Jun 03 ’25 when 5000.0 shares were purchased. Director, BIENAIME JEAN JACQUES completed a deal on Mar 25 ’25 to buy 7800.0 shares. Meanwhile, President and CEO SIEGALL CLAY B bought 0.14 million shares on Mar 26 ’25.
